ClinicalTrials.gg

Scleroderma, Diffuse clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 310 studies for Scleroderma, Diffuse across more than 10 countries. 76 are recruiting or about to start. 163 of them are mainly about Scleroderma, Diffuse (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
149
Recruiting
55
Terminated
34
Status unknown
24
Not yet recruiting
18
Withdrawn
13

Phase

Phase 2
92
Phase 1
48
Phase 3
43
Phase 4
7
Early Phase 1
5

Where

United States
153
France
40
Canada
34
United Kingdom
31
Turkey
26
Spain
25

Who develops what

Add Scleroderma, Diffuse to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 19 programs from 15 companies, 2 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Bristol-Myers Squibb, AbelZeta and Galderma Group here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
fludarabineRecent, limitedPhase 4 trial recorded
Evidence
  • NCT06733935 · Nkarta, Inc. · Phase 2 · live · background · “Fludarabine” · registered Dec 2024
Beijing Biotech18% of its industry studies11 study
CyclophosphamideRecent, limited
Evidence
  • NCT06733935 · Nkarta, Inc. · Phase 2 · live · background · “Cyclophosphamide” · registered Dec 2024
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed11 study
RituximabRecent, limited
Evidence
  • NCT06655896 · Novartis · Phase 2 · live · comparator · “rituximab” · registered Oct 2024
Hoffmann-La Roche45% of its industry studiesUS: Hoffmann-La Roche (FDA 1997) + 3 othersEU: Hoffmann-La Roche (EMA 1998) + 6 others11 study

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 19 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.PRO-203 · Prolium Bioscience, Inc · Phase 2 registry mapping onlyNCT07641634 A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. — primary endpoint: Incidence of Adverse Events and Laboratory Abnormalities [Safety and Tolerability] · 44 enrolled
  • May 2027 est.tibulizumab · Zura Bio Inc · Phase 2 registry mapping onlyNCT06843239 Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) — primary endpoint: [Period 1] Change from baseline in modified Rodnan Skin Score (mRSS) at 24 weeks · 80 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Scleroderma, Diffuse studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Alkylating agents 3 open · Antimetabolites 2 open · PDE5 inhibitors 1 open · Endothelin receptor antagonists 10 · Tyrosine kinase inhibitors (TKIs) 5

Coming up

27studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger. 10 (18%) take children under 18. 3 (5%) are for women only and 0 (0%) for men only; 10 (18%) take healthy volunteers.

Recruiting studies that take each age, of 55
AgeWomenMen
1010 (18%)9 (16%)
1853 (96%)50 (91%)
3053 (96%)50 (91%)
4054 (98%)51 (93%)
5054 (98%)51 (93%)
6552 (95%)49 (89%)
7540 (73%)39 (71%)
8534 (62%)33 (60%)

Across all 310 studies, recruiting or not: 33% stop at 75 or younger and 13% at 65; 12% take children; 3% are for women only and 0% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Scleroderma, Diffuse studies take

Of 24 phase 2 interventional studies under Scleroderma, Diffuse, half reached primary completion within 48 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 248 mo31–108 · 24 studies——
Interventional, no phase16 mo4–28 · 53 studies—14 mo4–27 · 51 studies
Observational80 mo44–… · 32 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 17, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 310. Browse all 310 → or search them.